PDT Partners’s MaxCyte MXCT Stock Holding History

PDT Partners’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-36,248	Closed	-$113K	–	629
2023 Q3	$113K	Hold	36,248	–	–	0.01%	553
2023 Q2	$166K	Sell	36,248 -9,403	-21%	-$43.2K	0.02%	514
2023 Q1	$226K	Buy	+45,651	New	+$225K	0.03%	495
2022 Q3	–	Sell	-16,080	Closed	-$76K	–	996
2022 Q2	$76K	Buy	+16,080	New	+$79.2K	0.01%	902

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PDT Partners's MXCT Position: Q4 2023 in Review

PDT Partners sold out of MaxCyte (MXCT) in Q4 2023, closing a stake of 36,248 shares — an estimated $113K sold.

PDT Partners first reported a position in MXCT in Q2 2022 and held it in 4 quarters. The position peaked at $226K in Q1 2023. 120 funds tracked by Wall St. Rank hold MXCT as of Q4 2023.

PDT Partners reported no remaining MaxCyte position as of Q4 2023 after selling out during the quarter.
PDT Partners sold 36,248 MaxCyte shares in Q4 2023, an estimated $113K.
PDT Partners first reported a position in MaxCyte in Q2 2022 and held it in 4 quarters.
PDT Partners's MaxCyte position peaked at $226K in Q1 2023.
120 funds tracked by Wall St. Rank held MaxCyte as of Q4 2023.

Based on PDT Partners's 13F filing for Q4 2023, filed 14 Feb 2024.